Nektar Therapeutics (NKTR) Scheduled to Post Quarterly Earnings on Thursday

Nektar Therapeutics (NASDAQ:NKTR) will be announcing its earnings results after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). Nektar Therapeutics had a negative net margin of 190.09% and a negative return on equity of 133.64%. The business had revenue of $23.49 million during the quarter, compared to the consensus estimate of $17.24 million. During the same quarter last year, the business earned ($0.27) EPS. On average, analysts expect Nektar Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nektar Therapeutics Trading Up 4.1 %

NKTR traded up $0.06 during trading on Tuesday, reaching $1.39. 1,686,754 shares of the company’s stock were exchanged, compared to its average volume of 1,749,704. The firm has a fifty day moving average price of $1.28 and a two-hundred day moving average price of $1.34. The stock has a market capitalization of $254.95 million, a PE ratio of -1.56 and a beta of 0.61. Nektar Therapeutics has a one year low of $0.41 and a one year high of $1.93.

Analysts Set New Price Targets

Several brokerages recently issued reports on NKTR. BTIG Research reaffirmed a “buy” rating and set a $4.00 target price on shares of Nektar Therapeutics in a research report on Monday, September 30th. Piper Sandler began coverage on Nektar Therapeutics in a research note on Monday. They issued an “overweight” rating and a $7.00 price objective on the stock. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $3.50.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.